CORE--PEPTIDE SYNTHESIS AND ANTIBODY PRODUCTION

核心--多肽合成与抗体生产

基本信息

  • 批准号:
    6296025
  • 负责人:
  • 金额:
    $ 27.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-05-01 至 2000-04-30
  • 项目状态:
    已结题

项目摘要

The purpose of this Core is to provide synthetic peptides and polyclonal antisera required by the Projects of this Program to carry out structural, functional and mechanistic studies. The two PI's of this Core have collaborated for 25 years to design peptide immunogens and produce high affinity, high specificity antibodies towards peptides and proteins. Using the Merrifield automated solid phase approach to peptide synthesis, this Core will synthesize at the request of each PI of this Program Project a total of approximately 30 peptides (including phosphopeptides) per year. From among these 30 synthetic peptides or from expressed proteins, approximately seven will be selected every year as immunogens for the production of polyclonal antisera. Using the latest techniques for peptide/protein isolation and analysis, we would provide relatively large quantities (25 to 100 mg) of purified, fully characterized peptides. Preparative peptide purification will be achieved by reversed phase high performance liquid chromatography (RP- HPLC) in two solvent systems. Determination of purity will be accomplished using RP-HPLC, ion exchange chromatography on FPLC and capillary zone electrophoresis; characterization will use amino acid analysis, mass spectroscopy (MS) and Edman degradation when necessary. We will use conjugated synthetic peptides as immunogens to develop antibodies directed towards gene products predicted from the cDNA sequences or from amino acid sequencing of tryptic fragments of purified natural products. Peptides will be carefully designed in such a way that the same peptide can be coupled through a unique bond to a protein carrier or a chromatographic support to raise antibodies and facilitate their affinity purification. Alternatively, fusion proteins produced in bacteria or recombinant proteins using the baculovirus/insect cell system and provided by individual projects will be injected directly in rabbits for production of antisera. To reduce cross-reactivity with antigens other than the protein of interest, selected antisera will be immunoaffinity purified using the cognate peptide, recombinant protein, or fusion protein covalently bound to an agarose-based gel.
本核心的目的是提供合成肽和多克隆

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEAN E RIVIER其他文献

JEAN E RIVIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEAN E RIVIER', 18)}}的其他基金

Pharmacology of neuroendocrine peptides
神经内分泌肽的药理学
  • 批准号:
    7429659
  • 财政年份:
    2007
  • 资助金额:
    $ 27.95万
  • 项目类别:
Pharmacology of neuroendocrine peptides
神经内分泌肽的药理学
  • 批准号:
    6956158
  • 财政年份:
    2005
  • 资助金额:
    $ 27.95万
  • 项目类别:
Core--Analytical and Peptide Synthesis
核心--分析与肽合成
  • 批准号:
    6956184
  • 财政年份:
    2005
  • 资助金额:
    $ 27.95万
  • 项目类别:
CORE--CHARACTERIZATION AND SYNTHESIS OF NOVEL CONOTOXINS
核心——新型芋螺毒素的表征与合成
  • 批准号:
    6610801
  • 财政年份:
    2003
  • 资助金额:
    $ 27.95万
  • 项目类别:
CORE--CHARACTERIZATION AND SYNTHESIS OF NOVEL CONOTOXIN PEPTIDES
核心——新型芋螺毒素肽的表征与合成
  • 批准号:
    6564577
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
  • 批准号:
    6887348
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:
PHARMACOLOGY OF NEUROENDOCRINE PEPTIDES
神经内分泌肽的药理学
  • 批准号:
    6594591
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
  • 批准号:
    6473846
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:
Somatostatin Receptor-Selective Agonists and Antagonists
生长抑素受体选择性激动剂和拮抗剂
  • 批准号:
    6786662
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:
CORE--SOLID PHASE PEPTIDE SYNTHESIS AND HPLC/CZE
核心--固相肽合成与HPLC/CZE
  • 批准号:
    6577255
  • 财政年份:
    2002
  • 资助金额:
    $ 27.95万
  • 项目类别:

相似海外基金

BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3819816
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    4691285
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3815902
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY EQUIPMENT
生物医学设施设备
  • 批准号:
    3931637
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3961763
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3811789
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3937887
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    4690608
  • 财政年份:
  • 资助金额:
    $ 27.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了